AUTH/2221/3/09: Public Health Registrar v Reckitt Benckiser Healthcare (Gaviscon Advance) – No breach of Clause 2

📅 2009 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2221/3/09
ComplainantPublic health registrar
CompanyReckitt Benckiser Healthcare (UK) Limited
ProductGaviscon Advance (sodium alginate and potassium bicarbonate)
IssueAlleged Clause 2 breach based on cumulative recent Code breaches in promotion
Applicable Code year2008
Complaint received20 March 2009
Case completed12 May 2009
AppealNo appeal
Clauses considered in this caseClause 2
RulingNo breach of Clause 2

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A public health registrar complained that Reckitt Benckiser’s promotion of Gaviscon Advance (sodium alginate and potassium bicarbonate) had, due to cumulative recent Code breaches, brought discredit to and reduced confidence in the pharmaceutical industry (alleged Clause 2 breach).
  • The complaint relied on two earlier PMCPA cases about Gaviscon Advance materials in the BMJ:
    • AUTH/2138/7/08: two advertisements ruled misleading (breach of the Code; breach of Clause 7.2 in each ad) due to clinical inferences drawn from in vitro data.
    • AUTH/2205/2/09: a BMJ supplement reporting an advisory board was ruled to have breached the Code (breaches included Clauses 6.3, 7.2, 9.1, 12.1; and no breach of Clause 9.7 was ruled in that case, subject to an appeal at the time).
  • Reckitt Benckiser disputed that the earlier cases were connected or sufficiently serious/similar to amount to a Clause 2 breach, and described compliance actions (including training and process improvements).
⚖️

Outcome

  • No breach of Clause 2 was ruled.
  • The Panel nevertheless expressed concern that the earlier cases suggested an apparent poor knowledge of Code requirements, and noted the company had initiated a compliance programme including in-house training by an external consultant.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training